162 related articles for article (PubMed ID: 38279383)
1. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Tehlirian C; Peeva E; Kieras E; Scaramozza M; Roberts ES; Singh RSP; Pradhan V; Banerjee A; Garcet S; Xi L; Gale JD; Vincent MS; Krueger J
Lancet Rheumatol; 2021 Mar; 3(3):e204-e213. PubMed ID: 38279383
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
5. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Papp KA; Weinberg MA; Morris A; Reich K
Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
[TBL] [Abstract][Full Text] [Related]
6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
7. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
8. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
9. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
[TBL] [Abstract][Full Text] [Related]
11. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
Forman SB; Pariser DM; Poulin Y; Vincent MS; Gilbert SA; Kieras EM; Qiu R; Yu D; Papacharalambous J; Tehlirian C; Peeva E
J Invest Dermatol; 2020 Dec; 140(12):2359-2370.e5. PubMed ID: 32311398
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
14. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
[TBL] [Abstract][Full Text] [Related]
15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
16. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Tehlirian C; Singh RSP; Pradhan V; Roberts ES; Tarabar S; Peeva E; Vincent MS; Gale JD
J Am Acad Dermatol; 2022 Aug; 87(2):333-342. PubMed ID: 35398218
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
20. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]